Skip to main content
. 2018 Nov 29;2018(11):CD011274. doi: 10.1002/14651858.CD011274.pub2
Criterion Evidence Decision
Risk of bias Rafiq 2014 was at high risk of performance and detection bias; Kulik 2004 was at high risk of attrition bias Serious
Imprecision 410 participants Not serious: length of stay measured in all participants
Inconsistency Chi2 = 2.63, df = 1 (P = 0.27); I2 = 24% Serious: mean length of stay in control groups varied from 5.4 (Kulik 2004) to 17.2 days (NAFARM 2011)
Indirectness The indications for NSAID was prevention of atrial fibrillation in the largest study (NAFARM 2011) rather than analgesia Serious: the dose of naproxen in NAFARM 2011 was much lower than would be used for analgesia
Publication bias None of the studies were commercially sponsored Not serious